So far it looks promising but the advanced melanoma market is of course much smaller than for liver cancer.I would say there is a greater than 50% chance of failure if it gets to Phase III. Or should I say a more than 40% chance of success :-)
ACW This biotech stock raised $11M in a risk-off environment. Its Alzheimer's drug could change the game
History-making uranium sample grades and an imminent drill run. Infini Resources is poised to transform in 2025